<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Tumors of female reproductive system</journal-id><journal-title-group><journal-title xml:lang="en">Tumors of female reproductive system</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли женской репродуктивной системы</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1994-4098</issn><issn publication-format="electronic">1999-8627</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">190</article-id><article-id pub-id-type="doi">10.17650/1994-4098-2011-0-4-19-23</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>MAMMOLOGY. TOPICAL ISSUE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>МАММОЛОГИЯ. АКТУАЛЬНАЯ ТЕМА</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Therapeutic pathomorphism of malignancies: Clinical and morphological criteria. Classifications. Prognostic value of therapeutic pathomorphism in breast cancer and other tumors</article-title><trans-title-group xml:lang="ru"><trans-title>Лечебный патоморфоз злокачественных опухолей: клинические и морфологические критерии. Классификации. Прогностическое значение лечебного патоморфоза при раке молочной железы и других опухолях</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lisayeva</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Лисаева</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vishnevskaya</surname><given-names>Ya. V.</given-names></name><name xml:lang="ru"><surname>Вишневская</surname><given-names>Я. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Roshchin</surname><given-names>E. M.</given-names></name><name xml:lang="ru"><surname>Рощин</surname><given-names>Е. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Komov</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Комов</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kolyadina</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Колядина</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>irinakolyadina@yandex.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Department of Tumor Diagnosis, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences</institution></aff><aff><institution xml:lang="ru">Отделение диагностики опухолей ФГБУ РОНЦ им. Н.Н. Блохина РАМН</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Department of Pathologic Anatomy, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences</institution></aff><aff><institution xml:lang="ru">патологоанатомическое отделение ФГБУ РОНЦ им. Н.Н. Блохина РАМН</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Department of Oncology, Russian Medical Academy of Postgraduate Education, Moscow</institution></aff><aff><institution xml:lang="ru">кафедра онкологии РМАПО, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2011-11-18" publication-format="electronic"><day>18</day><month>11</month><year>2011</year></pub-date><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>19</fpage><lpage>23</lpage><history><date date-type="received" iso-8601-date="2014-08-20"><day>20</day><month>08</month><year>2014</year></date><date date-type="accepted" iso-8601-date="2014-08-20"><day>20</day><month>08</month><year>2014</year></date></history><permissions><copyright-year>2011</copyright-year><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://ojrs.abvpress.ru/ojrs/article/view/190">https://ojrs.abvpress.ru/ojrs/article/view/190</self-uri><abstract xml:lang="en"><p>Pathomorphism is one of the most important prognostic factors for breast cancer . The paper gives the notion of pathomorphism an d its types and the most commonly used classifications of tumor pathomorphological changes. It also considers the long-term results of neoadjuvant treatment in relation to pathomorphism.</p></abstract><trans-abstract xml:lang="ru"><p>Патоморфоз — один из важнейших факторов прогноза рака молочной железы. В статье дано понятие патоморфоза и его вари- антов, а также представлены наиболее распространенные классификации патоморфологических изменений в опухоли. Рассмот- рены отдаленные результаты неоадъювантного лечения в зависимости от патоморфоза.</p></trans-abstract><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>therapeutic pathomorphism</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>молочная железа</kwd><kwd>лечебный патоморфоз</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Патологоанатомическая диагностика опухолей человека. Руководство в двух томах. Под ред. Н.А. Краевского, А.В. Смольянникова. М.: Медицина, 1993. Т1; с. 130–58.</mixed-citation><mixed-citation xml:lang="ru">Патологоанатомическая диагностика опухолей человека. Руководство в двух томах. Под ред. Н.А. Краевского, А.В. Смольянникова. М.: Медицина, 1993. Т1; с. 130–58.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Apple S.K., Suthar F. How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy? Breast 2006;15(1):370–6.</mixed-citation><mixed-citation xml:lang="ru">Apple S.K., Suthar F. How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy? Breast 2006;15(1):370–6.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Miller I.D., Payne S., Ogston K.N. A new gistological grading system to assess response of breast cancer to primary chemotherapy. Int J Oncol 2002;20(4):791–6.</mixed-citation><mixed-citation xml:lang="ru">Miller I.D., Payne S., Ogston K.N. A new gistological grading system to assess response of breast cancer to primary chemotherapy. Int J Oncol 2002;20(4):791–6.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Chevallier B., Roche H., Olivier J.P. et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993;16:223–8.</mixed-citation><mixed-citation xml:lang="ru">Chevallier B., Roche H., Olivier J.P. et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993;16:223–8.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Sataloff D.M., Mason B.A., Prestipino A.J. et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995;180:297–306.</mixed-citation><mixed-citation xml:lang="ru">Sataloff D.M., Mason B.A., Prestipino A.J. et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995;180:297–306.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Penault-Llorca F., Abrial C., Raoelfils I. et al. Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer.</mixed-citation><mixed-citation xml:lang="ru">Penault-Llorca F., Abrial C., Raoelfils I. et al. Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><mixed-citation>Hum Pathol 2008;39:1221–8.</mixed-citation></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">7. Honkoop A.H., Pinedo H.M., De Jong J.S. et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 1997; 107:211–8.</mixed-citation><mixed-citation xml:lang="ru">Honkoop A.H., Pinedo H.M., De Jong J.S. et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 1997; 107:211–8.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">8. Burcombe R.J., Makris A., Richman P.I. et al. Evaluation of ER, PgR, Her-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005;92(1):147–55.</mixed-citation><mixed-citation xml:lang="ru">Burcombe R.J., Makris A., Richman P.I. et al. Evaluation of ER, PgR, Her-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005;92(1):147–55.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">9. Symmans W.F., Peintinger F., Hatzis C. et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414–22.</mixed-citation><mixed-citation xml:lang="ru">Symmans W.F., Peintinger F., Hatzis C. et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414–22.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">10. Kaufmann M., Hortobagyi G.N., Goldhirsch A. et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006;24:1940–9.</mixed-citation><mixed-citation xml:lang="ru">Kaufmann M., Hortobagyi G.N., Goldhirsch A. et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006;24:1940–9.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">11. www.mdanderson.org/breastcancer_RCB</mixed-citation><mixed-citation xml:lang="ru">www.mdanderson.org/breastcancer_RCB</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">12. Fisher E.R., Wang J., Bryant J. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002;95:681–95.</mixed-citation><mixed-citation xml:lang="ru">Fisher E.R., Wang J., Bryant J. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002;95:681–95.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">13. Fisher B., Brown A., Mamounas E. et al. Effect of preoperative chemotherapy on local- regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483–93.</mixed-citation><mixed-citation xml:lang="ru">Fisher B., Brown A., Mamounas E. et al. Effect of preoperative chemotherapy on local- regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483–93.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">14. Огнерубов Н.А. Неоадъювантная терапия местно-распространенного рака молочной железы. Автореф. дис. ... д-ра мед. наук. М., 1992.</mixed-citation><mixed-citation xml:lang="ru">Огнерубов Н.А. Неоадъювантная терапия местно-распространенного рака молочной железы. Автореф. дис. ... д-ра мед. наук. М., 1992.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
